{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T07:42:57Z","timestamp":1771659777274,"version":"3.50.1"},"update-to":[{"DOI":"10.1371\/journal.pntd.0011365","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000}}],"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:00:00Z","timestamp":1684454400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1190749"],"award-info":[{"award-number":["OPP1190749"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Onchocerciasis (\u201criver blindness\u201d) has been targeted for elimination. New treatments that kill or permanently sterilize female worms could accelerate this process. Prior studies have shown that triple drug treatment with ivermectin plus diethylcarbamazine and albendazole (IDA) leads to prolonged clearance of microfilaremia in persons with lymphatic filariasis. We now report results from a randomized clinical trial that compared the tolerability and efficacy of IDA vs. a comparator treatment (ivermectin plus albendazole, IA) in persons with onchocerciasis.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods and findings<\/jats:title>\n<jats:p>The study was performed in the Volta region of Ghana. Persons with microfiladermia and palpable subcutaneous nodules were pre-treated with two oral doses of ivermectin (150 \u03bcg\/kg) separated by at least 6 months prior to treatment with either a single oral dose of ivermectin 150 \u03bcg\/kg plus albendazole 400 mg (IA), a single oral dose of IDA (IDA1, IA plus diethylcarbamazine (DEC. 6 mg\/kg) or three consecutive daily doses of IDA (IDA3). These treatments were tolerated equally well. While adverse events were common (approximately 30% overall), no severe or serious treatment-emergent adverse events were observed. Skin microfilariae were absent or present with very low densities after all three treatments through 18 months, at which time nodules were excised for histological assessment. Nodule histology was evaluated by two independent assessors who were masked regarding participant infection status or treatment assignment. Significantly lower percentages of female worms were alive and fertile in nodules recovered from study participants after IDA1 (40\/261, 15.3%) and IDA3 (34\/281, 12.1%) than after IA (41\/180, 22.8%). This corresponds to a 40% reduction in the percentage of female worms that were alive and fertile after IDA treatments relative to results observed after the IA comparator treatment (P = 0.004). Percentages of female worms that were alive (a secondary outcome of the study) were also lower after IDA treatments (301\/574, 52.4%) than after IA (127\/198, 64.1%) (P = 0.004). Importantly, some comparisons (including the reduced % of fertile female worms after IDA1 vs IA treatment, which was the primary endpoint for the study) were not statistically significant when results were adjusted for intraclass correlation of worm fertility and viability for worms recovered from individual study participants.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Results from this pilot study suggest that IDA was well tolerated after ivermectin pretreatment. They also suggest that IDA was more effective than the comparator treatment IA for killing or sterilizing female <jats:italic>O<\/jats:italic>. <jats:italic>volvulus<\/jats:italic> worms. No other short-course oral treatment for onchocerciasis has been demonstrated to have macrofilaricidal activity. However, this first study was too small to provide conclusive results. Therefore, additional studies will be needed to confirm these promising findings.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Trial registration<\/jats:title>\n<jats:p>The study is registered at Cinicaltrials.gov under the number <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04188301\" xlink:type=\"simple\">NCT04188301<\/jats:ext-link>.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pntd.0011365","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T17:41:54Z","timestamp":1684518114000},"page":"e0011365","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["A randomized, open-label study of the tolerability and efficacy of one or three daily doses of ivermectin plus diethylcarbamazine and albendazole (IDA) versus one dose of ivermectin plus albendazole (IA) for treatment of onchocerciasis"],"prefix":"10.1371","volume":"17","author":[{"given":"Nicholas O.","family":"Opoku","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Doe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina","family":"Dubben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Fetcho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerstin","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter U.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shelter","family":"Gordor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles W.","family":"Goss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael E.","family":"Gyasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Achim","family":"Hoerauf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Augustine R.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Kanza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher L.","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Laryea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daphne","family":"Lew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmood A.","family":"Seidu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6336-3824","authenticated-orcid":true,"given":"Gary J.","family":"Weil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2023,5,19]]},"reference":[{"key":"pntd.0011365.ref001","first-page":"545","article-title":"Progress report on the elimination of human onchocerciasis, 2019\u20132020.","author":"WHO","year":"2020"},{"issue":"8","key":"pntd.0011365.ref002","doi-asserted-by":"crossref","first-page":"e0005424","DOI":"10.1371\/journal.pntd.0005424","article-title":"The global burden of disease study 2013: What does it mean for the NTDs?","volume":"11","author":"JR Herricks","year":"2017","journal-title":"PLoS Negl Trop Dis."},{"issue":"suppl_1","key":"pntd.0011365.ref003","doi-asserted-by":"crossref","first-page":"i71","DOI":"10.1093\/inthealth\/ihx039","article-title":"Progress toward elimination of onchocerciasis in the Americas","volume":"10","author":"M Sauerbrey","year":"2018","journal-title":"Int Health"},{"issue":"47","key":"pntd.0011365.ref004","first-page":"414","article-title":"Progress in eliminating onchocerciasis in the WHO Region of the Americas: doxycycline treatment as an end-game strategy.","volume":"93","author":"WHO","year":"2019","journal-title":"Wkly Epidemiol Rec"},{"issue":"9","key":"pntd.0011365.ref005","doi-asserted-by":"crossref","first-page":"e1825","DOI":"10.1371\/journal.pntd.0001825","article-title":"Proof-of-principle of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: final results of a study in Mali and Senegal.","volume":"6","author":"MO Traore","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"issue":"5","key":"pntd.0011365.ref006","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.4269\/ajtmh.16-0274","article-title":"The First Confirmed Elimination of an Onchocerciasis Focus in Africa: Abu Hamed, Sudan","volume":"95","author":"IM Zarroug","year":"2016","journal-title":"Am J Trop Med Hyg"},{"key":"pntd.0011365.ref007","first-page":"Doc02","article-title":"Current perspective of new anti-Wolbachial and direct-acting macrofilaricidal drugs as treatment strategies for human filariasis.","volume":"10","author":"A Ehrens","year":"2022","journal-title":"GMS Infect Dis."},{"issue":"1","key":"pntd.0011365.ref008","doi-asserted-by":"crossref","first-page":"e0005163","DOI":"10.1371\/journal.pntd.0005163","article-title":"Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa.","volume":"11","author":"PU Fischer","year":"2017","journal-title":"PLoS Negl Trop Dis."},{"issue":"3","key":"pntd.0011365.ref009","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/cid\/civ882","article-title":"Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis","volume":"62","author":"EK Thomsen","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"19","key":"pntd.0011365.ref010","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1706854","article-title":"A Trial of a Triple-Drug Treatment for Lymphatic Filariasis","volume":"379","author":"CL King","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"pntd.0011365.ref011","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1093\/cid\/ciz1050","article-title":"Efficacy and Safety of a Single Dose of Ivermectin, Diethylcarbamazine, and Albendazole for Treatment of Lymphatic Filariasis in Cote d\u2019Ivoire: An Open-label Randomized Controlled Trial","volume":"71","author":"CM Bjerum","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"6","key":"pntd.0011365.ref012","doi-asserted-by":"crossref","first-page":"e0008298","DOI":"10.1371\/journal.pntd.0008298","article-title":"Safety and efficacy of co-administered diethylcarbamazine, albendazole and ivermectin during mass drug administration for lymphatic filariasis in Haiti: Results from a two-armed, open-label, cluster-randomized, community study.","volume":"14","author":"CL Dubray","year":"2020","journal-title":"PLoS Negl Trop Dis."},{"issue":"2","key":"pntd.0011365.ref013","doi-asserted-by":"crossref","first-page":"e0009069","DOI":"10.1371\/journal.pntd.0009069","article-title":"An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs.","volume":"15","author":"P Jambulingam","year":"2021","journal-title":"diethylcarbamazine plus albendazole for lymphatic filariasis in India. PLoS Negl Trop Dis"},{"issue":"3","key":"pntd.0011365.ref014","doi-asserted-by":"crossref","first-page":"e0009294","DOI":"10.1371\/journal.pntd.0009294","article-title":"An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia","volume":"15","author":"T Supali","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"issue":"20","key":"pntd.0011365.ref015","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1056\/NEJMc1914262","article-title":"Single-Dose Triple-Drug Therapy for Wuchereria bancrofti\u20145-Year Follow-up","volume":"382","author":"CL King","year":"2020","journal-title":"N Engl J Med"},{"key":"pntd.0011365.ref016","volume-title":"Guideline: alternative mass drug administration regimens to eliminate lymphatic filariasis.","author":"WHO","year":"2017"},{"issue":"2","key":"pntd.0011365.ref017","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/bjo.71.2.78","article-title":"Ocular findings in a double-blind study of ivermectin versus diethylcarbamazine versus placebo in the treatment of onchocerciasis","volume":"71","author":"KY Dadzie","year":"1987","journal-title":"Br J Ophthalmol"},{"issue":"10154","key":"pntd.0011365.ref018","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0140-6736(17)32844-1","article-title":"Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial","volume":"392","author":"NO Opoku","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"pntd.0011365.ref019","doi-asserted-by":"crossref","first-page":"740","DOI":"10.4269\/ajtmh.21-0859","article-title":"A Reevaluation of the Tolerability and Effects of Single-Dose Ivermectin Treatment on Onchocerca volvulus Microfilariae in the Skin and Eyes in Eastern Ghana","volume":"106","author":"NO Opoku","year":"2021","journal-title":"Am J Trop Med Hyg"},{"key":"pntd.0011365.ref020","author":"CCRPS","year":"2022","journal-title":"Code of Federal Regulations and ICH Guidelines GCP Reference Guide"},{"key":"pntd.0011365.ref021","author":"MedDRA","year":"2020","journal-title":"Medical Dictionary for Regulatory Activities"},{"issue":"6","key":"pntd.0011365.ref022","doi-asserted-by":"crossref","first-page":"e1002839","DOI":"10.1371\/journal.pmed.1002839","article-title":"The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study.","volume":"16","author":"GJ Weil","year":"2019","journal-title":"PLoS Med"},{"issue":"Suppl 4","key":"pntd.0011365.ref023","first-page":"331","article-title":"Diagnosis and extirpation of nodules in human onchocerciasis","volume":"39","author":"EJ Albiez","year":"1988","journal-title":"Trop Med Parasitol"},{"key":"pntd.0011365.ref024","article-title":"Comparison of repeated doses of ivermectin versus ivermectin plus albendazole for treatment of onchocerciasis\u2014a randomized open-label clinical trial","author":"L Batsa Debrah","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"3\u20134","key":"pntd.0011365.ref025","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.exppara.2004.06.006","article-title":"Onchocerca volvulus: expression and immunolocalization of a nematode cathepsin D-like lysosomal aspartic protease","volume":"107","author":"A Jolodar","year":"2004","journal-title":"Exp Parasitol"},{"key":"pntd.0011365.ref026","doi-asserted-by":"crossref","first-page":"1099926","DOI":"10.3389\/fmed.2023.1099926","article-title":"Histopathological evaluation of Onchocerca volvulus nodules by microscopy and by digital image analysis for the study of macrofilaricidal drug efficacy.","volume":"10","author":"K Fischer","year":"2023","journal-title":"Front Med (Lausanne)."},{"issue":"4","key":"pntd.0011365.ref027","first-page":"390","article-title":"Histological examination of adult Onchocerca volvulus and comparison with the collagenase technique","volume":"39","author":"DW Buttner","year":"1988","journal-title":"Trop Med Parasitol"},{"issue":"6","key":"pntd.0011365.ref028","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1007\/s00436-009-1588-5","article-title":"Criteria for the differentiation between young and old Onchocerca volvulus filariae","volume":"105","author":"S Specht","year":"2009","journal-title":"Parasitol Res"},{"issue":"9328","key":"pntd.0011365.ref029","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(02)09456-4","article-title":"Effects of standard and high doses of ivermectin on adult worms of Onchocerca volvulus: a randomised controlled trial","volume":"360","author":"J Gardon","year":"2002","journal-title":"Lancet"},{"issue":"4","key":"pntd.0011365.ref030","first-page":"213","article-title":"The chemotherapy of onchocerciasis XX: ivermectin in combination with albendazole","volume":"46","author":"K Awadzi","year":"1995","journal-title":"Trop Med Parasitol"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0011365","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0011365","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T17:33:37Z","timestamp":1685640817000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0011365"}},"subtitle":[],"editor":[{"given":"Luc E.","family":"Coffeng","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,5,19]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0011365","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pntd.0011365","asserted-by":"object"}]},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,19]]}}}